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Hodgkin's lymphoma (HL), formerly called Hodgkin's disease, is a malignant tumor of the 
lymphatic system (Schnitzer, 2009). It was first recorded by Thomas Hodgkin in 1832, when 
he described seven patients suffering from enlargement of lymph nodes and spleen as a new 
disease entity (Thomas et al, 2002).  
Understanding of its pathogenesis remains unclear (Mueller, 1991). The cellular origin of 
this lymphoma was failed to be clearly identified by molecular biology studies. The 
characteristic Reed Sternberg cell is thought to be derived from the histiocytes, granulocytes 
and reticulum cells (Lee et al, 1993). But other studies suggest that these cells represent 
immature lymphoid cells (Diehl et al, 1990).  
Hodgkin's lymphoma was described microscopically for the first time by langhans in 1872 
(Langhans, 1872). Jachson and Parker (1947) described the first histological classification of 
Hodgkin's lymphoma in 1947, later on this classification was revised at Rye in 1966 and in 
1994 the Rye classification was incorporated into the revised European–American 
lymphoma classification (REAL). Accordingly, Hodgkin's lymphoma was classified into 
nodular lymphocyte predominant, nodular sclerosing, mixed cellularity, lymphocyte 
depletion and lymphocyte – rich classical disease (Cartwright and Watkins, 2004). 
2. Incidence 
The incidence of Hodgkin's lymphoma shows marked heterogeneity with respect to age, 
gender, race, geographic area, social class and histological subtype (Burke, 1992). Hodgkin's 
lymphoma is listed as a rare disease by the office of rare diseases (ORD) of the National 
Institutes of Health (NIH). This means that it affects less than 200.000 people in the US 
population. About 8000 new cases of Hodgkin's lymphoma occur each year in the United 
States. 1500 people in the US die from Hodgkin's lymphoma each year. It is more common 
in Caucasians (Lee et al, 1993). Asians have lower incidence than other races (Glaser and 
Hsu, 2002). The annual incidence of Hodgkin's lymphoma appears stable over the past 
several decades. Incidence in the United Kingdom is about 2.4 per 1000.000 per year. 
Worldwide prevalence rates vary, with more than 5.5 per 100.000 in Yemen and Lebanon 
and less than 1 per 100.000 in china and Japan. At least some of this variation appears to 







The incidence of Hodgkin's lymphoma has increased among adolescents and young adults 
in the Nordic countries in the past few decades, whereas it has decreased strikingly among 
those aged 40 years or more (Hjalgrim et al, 2001). In developing countries, Hodgkin's 
lymphoma appears more during childhood and its incidence decreases with age, while in 
developed countries, young children are rarely affected by Hodgkin's lymphoma in contrast 
with young adults where incidence increase with age (Thomas et al, 2002). It has a bimodal 
age distribution in both sexes, peaking in young adults (aged 15-34 y) and older individuals 
(>55years) (IARC, 1997). In the United States, Nodular sclerosing subtype predominates in 
young adults, while Mixed cellularity subtype is more common in children (aged 0-14 y) 
and older individuals (Grufferman and Delzell, 1984; IARC, 1997 & Muller and Grufferman, 
1999). From 2004-2008, the median age at diagnosis for Hodgkin's lymphoma was 38 years 
of age and approximately 12.3% were diagnosed under age 20 years and 27.7% above 55 
years of age. 
There are two peaks in the age-specific incidence of Hodgkin's lymphoma. For males there 
is one in men aged 30-34 and another in older men aged 75-79 years. For women the two 
peaks occur in women aged 20-24 and 70-79 (Yung and Linch, 2003). 
Hodgkin's lymphoma is the third most common cancer in people aged 15-29 years, and the 
sixth most commonly diagnosed cancer in children under 14 years (Yung and Linch, 2003 & 
Hoffbrand et al, 2011).  
The bimodal incidence curve has been postulated to represent two etiology processes. The 
first hypothesis suggests an infectious cause of the disease in young adults and other 
environmental causes for older age groups (Cole et al, 1968). 
Low childhood rates and high young adulthood rates were found in the USA and West 
Europe. The Baltic States and central and Eastern European countries had higher childhood 
rates than those seen in the United States and Europe, but had similar rates in young adults. 
The pattern in Latin America and other developed countries is more, whilst the rates in Asia 
remain low (Cartwright and Watkins, 2004). 
A significant increase in the incidence of Hodgkin's lymphoma in adolescents and young 
adults was observed in Nordic countries (Langhans, 1872), India (Reed, 1902) and North 
America in the period between 1960 and 1997 (Cartwright and Watkins, 2004). Also, 
decrease rates has been reported in older adults. 
Hodgkin's lymphoma is most common in children and young adults, between the ages of 15 
and 40. 
The mortality rates are low (0.4 per 100000 per year in the United Kingdom) due to the 
excellent response to treatment. Mortality increases with age and in Countries with less 
access to treatment (Hoffbrand et al, 2011). 
4. Male : Female ratio 
Overall male to female ratio is 1.4:1 (Hoffbrand et al, 2011). It is the third most commonly 
diagnosed cancer in people aged 15-29 years. There is a slight overall male predominance in 
the incidence of Hodgkin's lymphoma, which is most marked in the childhood form (Spitz et 
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al, 1989). In adolescents, the incidence between males and females are roughly equal. Data 
from Norway showed that a sex ratio of 1:1 is seen in the 15-34 age group which increase to 2:1 
in the 50 and over group (MacMahon, 1966). Hodgkin's lymphoma is nearly twice as common 
in males. It is higher in males than females and higher in whites than other races (Shenoy et al, 
2011). Men are affected by Hodgkin's lymphoma slightly more than women among all 
subtypes except for the nodular sclerozing subtype (Thomas et al, 2002). The observed male 
predominance is particularly evident in children, in whom 85% of the cases are in males. 
5. Season 
May studies have revealed peaks in the early months of the years especially in February and 
March (Douglas, 1998; Neilly et al, 1995; & Newell et al, 1985). 
6. Race 
Both Blacks and Asians had lower incidence rates than whites, which may suggest genetic 
resistance possibly related to HLA type. Hodgkin's lymphoma is relatively rare in Japan 
(age-adjusted incidence of 0.3 per 100.000 males) and China (age-adjusted incidence of 0.2 
per 100.000 males) in comparison to North America and Europe. Within the European 
Union the highest rates are in Austria and Greece and the lowest rates are in Spain and 
Slovakia, (Glaser and Hsu, 2002 & Shenoy et al, 2011). 
7. Relation to infections 
Hodgkin’s lymphoma is a complex of related conditions that are part mediated by infectious 
diseases, immune deficits and genetic susceptibilities. The descriptive epidemiology of 
Hodgkin's lymphoma suggests an infectious disease process underlying its aetiology in 
children and young adults (MacMahon, 1966). There is a relationship between Hodgkin's 
lymphoma and Epstein-Barr virus (EBV) infection (Evans and Gutensohn, 1984; Mueller et 
al, 1989 & Swerdlow, 2003). The mechanisms underlying this association are unknown and 
the virus has never been isolated from or identified in most of Hodgkin's lymphoma tissue 
(Cartwright and Watkins, 2004 & Gruffeman and Delzell, 1984). 
Patients with a history of infectious mononucleosis due to Epstein-Barr virus may have an 
increased risk of Hodgkin's lymphoma (Alexander et al, 2000; Hjalgrim et al, 2000 & Mueller 
and Grufferman, 1999). 
EBV is the main candidate suggested as the infection causing Hodgkin's lymphoma for 
several years. However EBV genome has been found only within the tumor in about 20-40% 
of Hodgkin's lymphoma cases with a prior diagnosis of infectious mononucleosis (Landgren 
and Caporaso 2007). Several studies suggest that EBV may be a transforming agent in 
Hodgkin's lymphoma. Patients with a history of EBV infection are at a 2-3 fold higher risk 
for development of Hodgkin's lymphoma (Thomas et al, 2002). Mueller et al. (1989) 
analyzed EBV titers in pre-disease sera and found an enhanced level of EBV activation prior 
to onset of Hodgkin's lymphoma. 
Many authors using novel molecular techniques found that EBV DNA is present in 
Hodgkin's lymphoma cases more frequently in developing countries than in developed 
countries (Glaser et al, 1997 & Zarate et al, 1995). In Western countries, about 50% of 






Reed-Sternberg cells in EBV positive patients show an expression pattern of EBV-encoded 
genes, termed type 2 latency, which resembles that found in endemic nasopharyngeal 
carcinoma or a subset of T-cell lymphomas (Thomas et al, 2002). Activated NFkB was found 
to be a characteristic feature of Reed-Sternberg cells (Bargou et al, 1996). This activation 
results in massive spontaneous apoptosis of Reed-Sternberg cells by downregulation of an 
antiapoptotic signaling network (Hinz et al, 2001). Many reports have noted geographic and 
familial clustering of Hodgkin's lymphoma (Smith et al, 1977; Vianna et al, 1971 & Vianna 
and Polan, 1973). Swedish investigators suggested that early exposure to viral infection may 
play a role in the pathogenesis of the disease (Chang et al, 2004). 
EBV strain subtypes identified within Reed-Sternberg cells vary geographically. EBV type 1 
is predominant in the United Kingdom, South America, Australia and Greece, whereas EBV 
type 2 is predominant in Egypt (Wrinreb et al, 1996). Mixed cellularity Hodgkin's 
lymphoma is more likely to be EBV-associated than nodular sclerosis subtype.  
Many studies have found significant increase in risk of Hodgkin's lymphoma among 
patients with AIDS in the developed countries (Grulich et al, 1999 & Serraino et al, 2000). In 
contrast, these increased risk have not been observed in Africa (Chokunonga et al, 1999; 
Dolcetti et al, 2001 & lazzi et al, 1998). In addition, other studies have demonstrated an 
increased incidence in HIV-positive intravenous drug users (Andrieu et al, 1993; Roithmann 
et al, 1990 & Rubio, 1994). 
Also, Human Herpes virus 6 (HHV-6), HHV-7, HHV-8 and cytomegalovirus infections were 
demonstrated in Hodgkin’s lymphoma patients (Gompels et al, 1993; Josephs et al, 1988 & 
Salahuddin et al, 1986). 
Patients with HIV infection have a 15- fold increase risk to develop Hodgkin's lymphoma 
than the general population (Biggar et al, 2006). They usually present at a more advanced 
age with associated extranodal involvement and B symptoms (Glaser et al, 2003). 
8. Socio-economic status 
The childhood form of Hodgkin's lymphoma tends to increase with increasing family size 
and decreasing socio-economic status. The young adult form is associated with a higher 
socioeconomic status in industrialized countries. The risk decreases significantly with 
increased sibship size and birth order (Westergard et al, 1997). It has been suggested that the 
risk of Hodgkin's lymphoma may be correlated to higher social classes in children and 
young adults (Alexander et al, 1991a & Alexander et al, 1991b). Reports regarding the socio-
economic status in older adults are conflicting (DeLong et al, 1984; Glaser et al, 2001 & 
Gutensohn, 1982).  
9. Occupational exposures 
It is not possible to conclude that a causal relationship exists between the various 
occupational exposures and risk of Hodgkin's lymphoma. Although one study reported that 
the physicians had a risk 80% higher than that of controls (Vianna et al, 1974), yet other 
studies did not found this increased risk (Grufferman et al, 1976; Matanoski et al, 1975 & 
Smith et al, 1974). Some studies reported an increased risk of Hodgkin's lymphoma in white 
men employed in woodworking or wood-related industries (Fonte et al, 1982; Milham and 
Hesser, 1967; Olsen and Sabroe, 1979 & Petersen and Milham, 1974). Conflicting results were 
www.intechopen.com
 
Epidemiology of Hodgkin's Lymphoma 
 
53 
reported regarding the association between Hodgkin's lymphoma and benzene exposure, 
rubber and chemical industries (La Vecchia et al, 1989; Lagorio et al, 1994; Rushton and 
Alderson, 1983; Schnatter et al, 1993; Sorahan et al, 1989 & Vianna and Polan, 1979). 
Smoking more than 14 cigarettes per day was associated with a 50% increased risk (Adami 
et al, 1998 & Paffenbarger et al, 1977). 
10. Familial incidence and genetic susceptibility 
There is 3 to 9 fold increased risk of developing Hodgkin's lymphoma in family members of 
these patients (Haim et al, 1982 & Mack et al, 1995). Razis et al. (1959) were the first to report 
a three fold risk in first-degree relatives of patients with Hodgkin's lymphoma. 
Swedish Cancer registry reported that Hodgkin's lymphoma was the fourth in a list of 
cancers with high familial incidence (Lindeiof and Eklund, 2001). Many oncogenes and 
tumor–suppressor genes have been studied, but no consistent mutation pattern has been 
identified (Thomas et al, 2002). Translocation [t (2;14) (P13;q32.3)] involving the BcL 11 a 
gene was reported in classic Hodgkin's lymphoma (Martin-Subero et al, 2002). 
Numerical and structural chromosomal alterations are frequent in Hodgkin's lymphoma 
patients but they lack any consistent pattern (Thomas et al, 2002). However, molecular 
clonal alterations such as gene amplifications or deletions reflect a distinct pattern of genetic 
instability. 
Aggregation in families and persons with specific human leukocyte antigen (HLA) type 
indicates genetic susceptibility (Burke, 1992 & Maggioncalda et al, 2011). Several reports 
recorded aggregation and clustering of Hodgkin's lymphoma patients in the same families and 
races which may suggest a genetic predisposition or exposure to a certain etiologic agent. 
The Antigens were found to be associated with Hodgkin's lymphoma: A1, B5 and B18 which 
might indicate that a disease susceptibility gene lies in or near the major histocompatibility 
region. These associations suggest that this disease is a result of genetic environmental 
interaction (Bodmer, 1973; Chakravarti et al, 1986; Robertson et al, 1987 & Svejgaard et al, 
1975). Also, concordance of Hodgkin's lymphoma in first degree relatives and in parent-
child pairs has been noted in many studies (Claser and Jarren, 1996) especially if they are of 
the same sex. 
Familial Hodgkin's lymphoma lacked the classic bimodal age distribution and has a peak 
between 15 and 34 years. It represents about 4.5% of all new cases (Kerzin-Storrar et al, 1983). 
Evidence of genetic susceptibility of this disease was supported by the finding that 
monozygotic twins have a 99-fold increased risk in contrast to dizygotic twins who have no 
increased risk to it (Mack et al, 1995). We found significant increase in the frequency of HLA 
DRB1*0403 and *1202 and DQ131*0604, *0201 and *0203 alleles which may confer 
suscepilibity (Al-Tonbary et al, 2004). Similar results were reported by Klitz et al. (1994) who 
reported a significant association of HLA class II alleles with Hodgkin's lymphoma and 
Harty et al. (2002) who reported that the DRB1*1501 allele is related to the development of 
familial Hodgkin's lymphoma particularly the familial nodular sclerosis type. The 
association of Hodgkin's lymphoma with different HLA-DRB1 and –DRQ1 alleles may be 
explained by three possibilities, first one implies that genes determining Hodgkin's 
lymphoma are located close to the major histocompatibility loci, and are thus transmitted 






cross-tolerance to a self-component (Woda and Rappaport, 1981). The third possibility is 
that the immunogenic responsiveness to oncogenic viruses may be linked to genes coding 
for HLA antigens (Zimadahl et al, 1999). In conclusion, certain environmental factors in 
addition to HLA genotypes might play a role in the occurrence of Hodgkin's lymphoma 
indicating a genetic–environmental interaction. 
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Table 1. Age standardized (World) incidence rates /100 000/year for Hodgkin's lymphoma 
in males and females (IARC, 1997 and Cartwright & Watkins, 2004). 
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WHO Africa region 5879 0.9 4893 0.8 0.9 
WHO East Mediterranean 
region 
7663 1.4 6004 1.2 0.9 
Less developed regions 40137 0.7 23698 0.5 0.7 
WHO South-East Asia region 11682 0.7 6276 0.4 0.6 
WHO Western Pacific region 8476 0.4 3478 0.2 0.5 
World 67887 1 30205 0.4 0.4 
WHO Europe region 19342 2 5898 0.5 0.3 
More developed regions 27750 2 6507 0.4 0.2 
WHO Americas region 14802 1.5 3649 0.3 0.2 
Table 2. Age-standardized incidence and mortality rates ranked by mortality to incidence 
ratio (case fatality ratio). Calculations are based on data from GLOBOCAN 2008.  
11. Hormonal factors 
Hormonal factors might have a role in the aetiology of this disease as evidenced by the male 
predominance in patients over 30 years and the higher risk in women aged less than 45 
years at diagnosis (Cartwright and Watkins, 2004). In addition, prolonged use of human 
growth hormone was considered as a risk factor for Hodgkin's lymphoma. 
12. Conclusion 
Hodgkin's lymphoma is a malignant tumor of the lymphatic system. It arises from germinal 
center or post germinal center B cells. It has a unique cellular composition, containing a 
minority of neoplastic cell (Reed- Sternberg cells and their variants) in an inflammatory 
background. By 1902, the characteristic giant cells of Hodgkin's lymphoma were recognized 
by Sternberg and Reed.  
The incidence of Hodgkin's lymphoma shows marked heterogeneity with respect to age, 
gender, race, geographic area, social class and histological subtype. 
 About 3200 deaths were attributed to Hodgkin's lymphoma annually in the United 
States. 
 About 8000 new cases of Hodgkin's lymphoma occur each year in the United States. 
 It is nearly twice as common in males. 
 It is more common in Caucasians 
 There are 3 age periods: 0-14 years, 15-34 years and over 50 years. 
 A significant peak in months of February and March were observed 
 There is no direct person to person spread of Hodgkin's lymphoma 
The descriptive epidemiology of Hodgkin's lymphoma suggests an infectious disease 
process underlying its aetiology in children and young adults. There is a relationship 
between Hodgkin's lymphoma and Epstein-Barr virus infection. The mechanisms 
underlying this association are unknown and the virus has never been isolated from or 






risk of Hodgkin's lymphoma among patients with AIDS. Also human herpes virus 6 (HHV-
6), 7,8 and CMV infections were demonstrated in patients with Hodgkin's lymphoma than 
in controls. Mixed cellularity subtype is more likely to be EBV-associated than nodular 
sclerosis subtype. 
The higher the socioeconomic status of person, the greater the risk in the young adult 
disease. It is not possible to conclude that a causal relationship exists between the 
occupational exposures and risk of Hodgkin's lymphoma. Smoking more than 14 cigarettes 
per day was associated with a 50% increased risk. Increased incidence in males may suggest 
hormonal background. Several reports record aggregation of Hodgkin's lymphoma patients 
within the same family. 
Several studies of HLA typing showed that some AGs were associated with Hodgkin's 
lymphoma. This association might indicate that a disease susceptibility gene lies in or near 
the major histocompatibility region. These associations suggest that this disease is a result of 
genetic environmental interaction. 
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